ChinaVenture reported on March 14 that Jiangsu Meifengli Medical Technology Co., Ltd. (referred to as: Meifengli) completed the latest round of financing. This round is led by a leading domestic top fund, with a total transaction volume of 100 million yuan. The funds will be used to promote the operation of the Suzhou preclinical GLP experimental platform (Suzhou Golden Wing Medical Technology Co., Ltd.) and the construction of the Taizhou Phase II preclinical experimental platform , to further improve the service capability of Meifengli.
According to public information, Meifengli was founded by a team of well-known domestic doctors represented by Dr. Wei Xufeng in China Medical City, Taizhou, Jiangsu Province in 2018. It is a comprehensive large animal experiment center specializing in preclinical experimental research on medical devices.
Since its establishment, Meifengli has completed more than 300 preclinical animal experiments of innovative medical device products. Accreditation and business cooperation with medical device testing institutes and professional testing institutions.
media reports
Arterial Network Arterial Network Investment Group Yiou Investment China Network
related events
- Meifengli completed the A-round financing of 100 million yuan2023-03-14
- Laboratory animal scientific research service provider Lingfu Biology completed a pre-A round of financing exceeding 200 million yuan2022-04-25
- Juyi Technology completed the B-round financing of more than 100 million RMB2021-07-14
This article is transferred from: https://readhub.cn/topic/8o8KWQMEfLs
This site is only for collection, and the copyright belongs to the original author.